poisar

Stocks · News reference

Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est

Aug 6, 2026, 11:05 AMBenzinga Newsdesk

Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LGND
Source
benzinga
Observed
Aug 6, 2026, 11:05 AM
Checked
Aug 6, 2026, 11:05 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 11:00 AMNa

    Ligand to Participate in September Investor Conferences

    Ligand Pharmaceuticals announced that its senior management team will participate in three upcoming investor conferences in September 2026: Wells Fargo Healthcare Conference (September 8), Citi 2026 Biopharma Back to School Conference (September 10), and H.C. Wainwright 28th Annual Global Investment Conference (September 14). The company will host fireside chats and one-on-one meetings with investors at these events.

    Read original at globenewswire-inc
    LGND